A Phase I Trial of Radioimmunotherapy (Y-90-Mx-DTPA-cT84.66) After Completion of Radiation Therapy Alone, or Radiation Therapy Plus Systemic Therapy in Unresectable or Medically Inoperable, Non-metastatic CEA-Producing Stage I-IIIB Non-Small Cell Lung Cancer.
Latest Information Update: 18 Sep 2021
At a glance
- Drugs Anti-CEA monoclonal antibody 111In-mT84-66 (Primary) ; Anti-CEA monoclonal antibody cT84-66-Y-90 (Primary) ; Carboplatin; Cisplatin; Etoposide; Paclitaxel
- Indications Non-small cell lung cancer
- Focus Adverse reactions
- 13 Feb 2018 Biomarkers information updated
- 08 Aug 2013 Planned end date changed from 1 Aug 2013 to 1 Jul 2014 as reported by ClinicalTrials.gov.
- 08 Aug 2013 Status changed from completed to active, no longer recruiting as reported by ClinicalTrials.gov.